Sartorious Octet R8 System

赛多利斯八位位组 R8 系统

基本信息

  • 批准号:
    10429632
  • 负责人:
  • 金额:
    $ 24.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-06-17 至 2023-06-16
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY / ABSTRACT The proposed S10 project entitled “Octet R8 System for Molecular Interaction Studies in Infectious and Non-infectious Diseases” is to respond to PAR-21-125 Basic Instrumentation Grant (BIG) Program. The mission of the Analytical Instrumentation Core (AIC) at Boston Medical Center (BMC) and Boston University (BU) is to provide support and training to investigators through cutting-edge analytical instruments and services to facilitate research and education. The ultimate goal is to contribute to the understanding of the pathogenesis, diagnosis, and treatment of a diverse range of human diseases. The AIC meets this goal by providing access to modern, sophisticated high-priced instruments that are necessary to advancing the research of multiple biomedical investigators. These instruments are typically cost-prohibitive for individual scientists to purchase, operate, and maintain. Based on feedback from our investigators, having highly sensitive approaches for identifying and quantifying intramolecular interactions between antibodies, receptors, peptides, small molecules, and viruses have consistently been reported as an AIC service of the greatest need. This is especially relevant because many groups have started more translational projects over the past several years (particularly because of the current pandemic) and require the ability to quantitatively detect binding between novel targets and therapeutics. This desire from multiple investigators has led us to explore the possibility of purchasing a Sartorius 8-channel Octet biolayer interferometry (BLI) R8 system. Industry- leading BLI analytical instruments precisely and accurately monitor binding between two different molecules in real-time. The Octet R8 will provide investigators a highly sensitive and reliable way to conduct binding assays, to quantify proteins, antibodies, peptides and small molecules, and to directly monitor the kinetics of binding events and interactions between biomolecules from in-vitro and ex-vivo studies. The AIC provides services to more than 150 investigators/labs, and has over 10 NIH funded projects that would directly utilize the Octet R8. Presence of BLI services will allow researchers to perform their projects with greater precision and sensitivity. We propose that the Octet-R8 will be housed at the AIC, which is located on the BU Medical Campus. However, it will still be equally accessible to investigators across the entire research community. This will be highly beneficial because the AIC has extensive experience and a magnificent record of accomplishment regarding instrument maintenance and training users. The instrument will be assured to be in excellent working condition, thus minimizing any potential down time. The institution will provide substantial financial support and there is also an advisory committee to assist with biosafety needs, publications, and annual progress reports. Investment in this equipment will allow our investigators to conduct studies of high significance for basic, translational and clinical research into infectious diseases, vaccine development, diabetes, heart disease, obesity, kidney disease, autoimmune diseases, cardiovascular diseases, and drug development.
项目摘要/摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Manish Sagar其他文献

Manish Sagar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Manish Sagar', 18)}}的其他基金

Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission
抗体依赖性细胞毒性和 HIV-1 母婴传播
  • 批准号:
    10707299
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission
抗体依赖性细胞毒性和 HIV-1 母婴传播
  • 批准号:
    10630722
  • 财政年份:
    2022
  • 资助金额:
    $ 24.91万
  • 项目类别:
HIV-1 mucosal transmission and persistence
HIV-1粘膜传播和持续性
  • 批准号:
    10355517
  • 财政年份:
    2019
  • 资助金额:
    $ 24.91万
  • 项目类别:
HIV-1 mucosal transmission and persistence
HIV-1粘膜传播和持续性
  • 批准号:
    10116270
  • 财政年份:
    2019
  • 资助金额:
    $ 24.91万
  • 项目类别:
HIV-1 mucosal transmission and persistence
HIV-1粘膜传播和持续性
  • 批准号:
    10596478
  • 财政年份:
    2019
  • 资助金额:
    $ 24.91万
  • 项目类别:
Identification and characterization of individuals with elite anti-HIV-1 ADCC
精英抗 HIV-1 ADCC 个体的鉴定和特征描述
  • 批准号:
    9757695
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
The effects of opioid use on HIV-1 reservoir dynamics
阿片类药物的使用对 HIV-1 病毒库动态的影响
  • 批准号:
    10673865
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
The effects of opioid use on HIV-1 reservoir dynamics
阿片类药物使用对 HIV-1 病毒库动态的影响
  • 批准号:
    10620076
  • 财政年份:
    2018
  • 资助金额:
    $ 24.91万
  • 项目类别:
CD1a Vaginal Dendritic Cells and HIV-1 Acquisition in the Female Genital Tract
CD1a 阴道树突状细胞和女性生殖道中 HIV-1 的获得
  • 批准号:
    8846903
  • 财政年份:
    2015
  • 资助金额:
    $ 24.91万
  • 项目类别:
CD1a Vaginal Dendritic Cells and HIV-1 Acquisition in the Female Genital Tract
CD1a 阴道树突状细胞和女性生殖道中 HIV-1 的获得
  • 批准号:
    9145066
  • 财政年份:
    2015
  • 资助金额:
    $ 24.91万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 24.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了